China NMPA Approval Tracker
China Deals Tracker
China Biotech Fundraising Tracker
China Regulatory Tracker
China Approved its First Cell Therapy
On June 22, NMPA green-lighted Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B cell lymphoma.
NMPA Re-elected as ICH Management Committee Member, ...
"The NMPA stands in the international arena with clear goals and intentions and will actively participate in the ICH’s international affairs in the future."
New Regulations for Post-Market Drug Changes Remain...
Recently, the National Medical Products Administration issued regulations for post-approval changes in medicinal products (for pilot implementation).
Copyright © 2016-2021 PharmaDJ .All Rights Reserved. Suggestions and feedback: